Stock fact sheet · data as of
Bioceres Crop Solutions Corp. (BIOX): fair value, margin of safety and Wheel Score
Ticker symbol BIOX · Basic Materials · Agricultural Inputs · Argentina · Speculative
Is BIOX undervalued?
BIOX has a margin of safety of 99%: the stock closed at 0.2534 on 5 Nov 2026 against a GLS average fair value of 18.64. 1 of the 1 valuation models that produced a number sit above the price. Our scans treat a discount this large as a strong starting point for a cash-secured put, not as a verdict - the fair value is a model output, and a wide gap can mean the models are missing something the market knows.
Only 1 of the nine models produced a value (10 Cap); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files BIOX under Speculative - it is losing money or its Piotroski health score is 3 or lower - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for BIOX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | 18.64 | +7257% | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10% |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -3.01 | -1287% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 8.00 | +3057% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: BIOX passes 3 of the nine Piotroski tests. Our scans drop the stock at the health filter; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is 5.4 out of 10: a record that is solid on some of the four parts the score weighs (returns on capital, pricing power, lasting growth, balance sheet) and weaker on others.
Returns on capital are thin or negative - ROIC -83.5%, ROE -589.0%, ROA -48.9% - with debt at 6.06 times equity and a free-cash-flow yield of 338.7%. Debt of 6.06 times equity is on the high side for the sector and is worth checking against the cash flow before treating the stock as a long-term hold.
Bioceres Crop Solutions Corp. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 98%, License 2% (quarter Q4 FY2022).
Institutional ownership scores 2/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 3 / 9 | ROIC | -83.5% |
|---|---|---|---|
| GLS Moat | 5.4 / 10 | ROE | -589.0% |
| Debt / equity | 6.06 | ROA | -48.9% |
| Free-cash-flow yield | 338.7% | Payout ratio | 0% |
| Institutions | 2 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 27: Weak
BIOX scores 27 out of 100 on the Wheel Score, in the Weak band (under 50): it fails filter 1, options that actually trade - options too quiet (4,386 open interest, 77 a day); and filter 2, a real business, not a gamble - speculative (a loss, or a weak Piotroski score); and filter 4, financially healthy - Piotroski 3/9 (under 6); and filter 6, no serious red flags - Red Flags score 45 (under 60); and filter 7, a premium worth selling - implied volatility 352% (over 80%); and filter 8, big enough - market cap $16M (under $1.0B); and filter 9, not a penny stock - price 0.25 (under $5), and the parts are thin too - value strong, premium weak, moat fair, health weak, red flags weak, option trading weak, stability fair. The score is not a judgement on the company; it says the price, quality and premium do not line up for selling puts on it today.
Implied volatility is 352%, above the 80% ceiling of the Wheel Trade Filter on premium. The premium looks generous, but moves of that size can blow through any strike. Chain open interest is 4,386 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 298k shares a day on a market cap of $16M, with a beta of 0.47 - a low beta, so day-to-day moves are smaller than the market's; the Stability part of the Wheel Score rates that fair.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Fails | options too quiet (4,386 open interest, 77 a day) |
| 2 | A real business, not a gamble | Fails | speculative (a loss, or a weak Piotroski score) |
| 3 | Below fair value | Passes | Trading below the nine-model average fair value (margin of safety above 0) |
| 4 | Financially healthy | Fails | Piotroski 3/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Fails | Red Flags score 45 (under 60) |
| 7 | A premium worth selling | Fails | implied volatility 352% (over 80%) |
| 8 | Big enough | Fails | market cap $16M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 0.25 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Strong | 99% below fair value | |
| Premium | Weak | implied volatility 352% | |
| Moat | Fair | moat 5.4/10 | |
| Health | Weak | Piotroski 3/9 | |
| Red Flags | Weak | Red Flags score 45/100 | |
| Option trading | Weak | 77 contracts a day, 4,386 open interest | |
| Stability | Fair | beta 0.47, $16M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
Bioceres Crop Solutions Corp. reports earnings on 12 Nov 2026 - inside the 14-day window the Sunday Scan avoids, because a put sold now would carry the report's gap risk.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Agricultural Inputs
The 12 companies below are the closest to Bioceres Crop Solutions Corp. by market cap within the Agricultural Inputs industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| SEED Origin Agritech Limited | 0.7202 | - | - | 8No options | $10M |
| AVD American Vanguard Corporation | 0.9759 | - | - | 9Weak | $29M |
| ITFS Itafos Inc. | 1.52 | 2.59 | +42% | 30No options | $295M |
| IPI Intrepid Potash, Inc. | 31.28 | 33.00 | +5% | 33Weak | $421M |
| BWEL JG Boswell Company | 593.58 | 1,715.58 | +65% | 29No options | $566M |
| FMC FMC Corporation | 6.42 | 57.28 | +89% | 37Weak | $804M |
| RKDA Arcadia Biosciences, Inc. | 0.1582 | - | - | 13No options | $245K |
| UAN CVR Partners, LP | 112.02 | 186.77 | +40% | 51Fair | $1.2B |
| SMG The Scotts Miracle-Gro Company | 67.19 | 57.85 | -16% | 32Weak | $3.9B |
| ICL ICL Group Ltd | 4.58 | 4.07 | -12% | 37Weak | $5.9B |
| MOS The Mosaic Company | 21.61 | 21.49 | -1% | 32Weak | $6.9B |
| CTVA Corteva, Inc. | 12.26 | 4.89 | -151% | 37Weak | $8.2B |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about BIOX
Is BIOX undervalued right now?
By the GLS models, yes: at 0.2534 the stock is 99% below the average fair value of 18.64 (data as of 5 Nov 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of BIOX and what does it mean?
BIOX scores 27 out of 100 (Weak) - it fails Wheel Trade Filters 1, 2, 4, 6, 7, 8, 9. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for BIOX?
18.64 per share as of 5 Nov 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Bioceres Crop Solutions Corp. report earnings next?
The next earnings report is due on 12 Nov 2026, 7 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does BIOX have listed options, and how liquid are they?
Yes. The nightly snapshot found 24 listed contracts with 4,386 open interest across all expiries and implied volatility of 352% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.